Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

The NCCN has updated its breast cancer guidelines, designating Novartis' Kisqali as a Category 1 preferred CDK4/6 inhibitor ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

"If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who currently ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Entresto Sales Growth: 26% increase in Q3. Cosentyx Sales Growth: 28% increase, with 38% growth in the US. Kisqali Sales ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...